EUVIMEDEUVIMED entdecken
Crossref

Impact of Persistent Hypogonadism on Overall Survival After Androgen Deprivation Therapy in Localized Prostate Cancer Patients: Long-Term Prospective Data

Abdenour Nabid, Nathalie Carrier, Éric Vigneault, André-Guy Martin, Thu Van Nguyen, Jean-Paul Bahary, Peter Vavassis, Boris Bahoric, Marc-André Brassard, Robert Archambault, François Vincent, Redouane Bettahar und 3 weitere

International Journal of Radiation Oncology*Biology*Physics · 2025

DOI: 10.1016/j.ijrobp.2025.09.062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2025. Verfasst von Abdenour Nabid und 14 weiteren Autor:innen. Beteiligte Einrichtung: Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Québec, Canada…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Androgen Antagonists, Testosterone, Hypogonadism. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The impact of persistent hypogonadism post-androgen deprivation therapy (ADT) on overall survival (OS) of patients with prostate cancer (PCa) is poorly documented. We compared OS between patients who recovered testosterone and those who did not after ADT. METHODS AND MATERIALS: Patients with PCa with intermediate- or high-risk disease were treated with ADT for 6, 18, or 36 months plus radiation therapy in 2 randomized trials. We compared OS between patients who recovered testosterone to a normal level to those who did not, using the log rank test. Multivariable Cox analysis to predict OS included recovered testosterone, age, Zubrod performance, comorbidities, baseline prostate specific antigen, Gleason score, stage, and ADT duration. To avoid immortal time bias, we performed a landmark analysis for each cohort. RESULTS: The median follow-up was 16.6 years. Patients not recovering testosterone to a normal level were older, with more associated medical comorbidities. All the results are reported respectively for the 6-, 18-, and 36-month ADT cohorts. Testosterone recovery rates, to normal level, were 76.7%, 58.6%, and 45.3% with a median time to testosterone recovery of 1.64, 3, and 5 years, respectively. The 10-year OS rates were significantly higher in patients recovering testosterone: 77% versus 61%, P < .001; 73% versus 51%, P < .001; and 78% versus 62%, P < .001. However, multivariable analyses with landmark time points failed to show testosterone recovery as an independent predictor. The study is limited by its post hoc analysis. CONCLUSIONS: In patients with PCa, our study shows that persistent hypogonadism post-ADT is associated with worse survival, particularly in older patients with medical conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAndrogen AntagonistsTestosteroneHypogonadismHumansMaleAgedMiddle AgedProspective StudiesProstate-Specific AntigenAge FactorsTime FactorsAged, 80 and overNeoplasm GradingFollow-Up StudiesComorbidity

Substanzen

Androgen AntagonistsTestosteroneProstate-Specific Antigen

Autor:innen und Institutionen

  • Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Québec, Canada. Electronic address: abdenour.nabid@usherbrooke.ca.
  • Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Québec, Canada.
  • CHU de Québec - Université Laval, Québec, Canada.
  • Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
  • Hôpital Maisonneuve-Rosemont, Montréal, Québec, Canada.
  • Hôpital Général Juif de Montréal, Montréal, Québec, Canada.

Zitieren

APA

Nabid, A., Carrier, N., Vigneault, É., Martin, A. G., Nguyen, T. V., Bahary, J. P., Vavassis, P., Bahoric, B., Brassard, M. A., Archambault, R., Vincent, F., Bettahar, R., Duclos, M., Wilke, D., & Souhami, L. (2025). Impact of Persistent Hypogonadism on Overall Survival After Androgen Deprivation Therapy in Localized Prostate Cancer Patients: Long-Term Prospective Data. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.09.062

Vancouver

Nabid A, Carrier N, Vigneault É, Martin AG, Nguyen TV, Bahary JP, et al. Impact of Persistent Hypogonadism on Overall Survival After Androgen Deprivation Therapy in Localized Prostate Cancer Patients: Long-Term Prospective Data. International Journal of Radiation Oncology*Biology*Physics. 2025. doi:10.1016/j.ijrobp.2025.09.062

BibTeX
@article{Nabid2025,
  author = {Nabid, Abdenour and Carrier, Nathalie and Vigneault, Éric and Martin, André-Guy and Nguyen, Thu Van and Bahary, Jean-Paul and Vavassis, Peter and Bahoric, Boris and Brassard, Marc-André and Archambault, Robert and Vincent, François and Bettahar, Redouane and Duclos, Marie and Wilke, Derek and Souhami, Luis},
  title = {Impact of Persistent Hypogonadism on Overall Survival After Androgen Deprivation Therapy in Localized Prostate Cancer Patients: Long-Term Prospective Data},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2025},
  doi = {10.1016/j.ijrobp.2025.09.062}
}
Kostenlos starten →